登录

Xinkairui Snares $1.4M in Series A Funding

作者: Mailman 2020-01-02 17:49
芯凯瑞生物
企业数据由 动脉橙 提供支持
高端体外诊断仪器及试剂产品开发商 | A轮 | 运营中
中国-广东
2019-12-28
融资金额:数千万人民币
幂方健康基金
查看

According to PEdaily.cn, microfluidic devices manufacturer Xinkairui Biological ("Xinkairui") has closed on its tens of millions of yuan (US$1.4 million) Series A financing, led by Mefund Capital with participation from Shenzhen Investment Holding Co., Ltd. 


The point-of-care testing (POCT) analysis system developed by Xinkairui is based on microfluidic chips. The POCT analysis system has the characteristics of small, portable, to be handheld and meets the needs of many clinical scenes. This device can directly detect whole blood, serum and plasma samples and interpret the results after several minutes of detection, making it possible to use in outpatient and emergency departments and surgical departments in hospitals, community hospitals, township hospitals, nursing homes, private clinics and even at home.


Dou Jiahua, the founder of Xinkairui, holds a PhD in electrical engineering from the University of Toronto, Canada, and has over 15 years of research and development experience in micro/nano manufacturing, integrated photonics and microfluidics devices. The co-founder Chen Lu holds a PhD in analytical chemistry from the University of Toronto in Canada and has over 15 years of experience in innovative research, product development, and management of real-time diagnostics.


>>>>

About Mefund Capital


Founded in 2014 at China's financial hub-Shanghai, Mefund Capital is an investment fund.


The business of Mefund Capital has reached many parts of China, with offices branches established in Beijing, Shenzhen, Zhejiang, Fujian, Shandong, and Jiangxi. Currently, it manages11 investment funds, of which the amount value has reached to nearly 800 million yuan.


Mefund Capital mainly invests in the healthcare and bioscience industry. The financial services include equity investments(VC/PE), PIPE, FOF (Fund of Funds), securities investing, M&A and etc.


>>>>

About Shenzhen Investment Holding Co., Ltd. ("SIHC")


SIHC is a state-owned investment company and comprehensive financial holding group established in October 2004 on the basis of the former three state-owned assets management companies in Shenzhen, China. Based on the urban development strategy, the company has become a global platform for innovative companies and resources. Focusing on scientific and technological innovation, SIHC is committed to the construction of a modern, international and innovative city. By the end of 2017, the company had AUM of about 500 billion yuan.

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

Tisenc Medical Closes on ¥80M Series B Financing

Wellgrow Techonogy Snags $1.4M in Series A Financing, Led by Green Pine Capital Partners

VivaChek Snags Nearly $14.2M in Series C Round, Developing POCT Products

Bigfish Bio-tech Completes $1.4M Series A Financing, Launching Handheld Molecular POCT

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Elpiscience Completes $100M Series B Financing

2020-01-02
下一篇

Mygene Closes on $14M Series B Financing, Led by Shenzhen Capital Group and CASH Capital

2020-01-02